ArticleCancers2021
Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 40 citations in OpenAlex.
- Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity.Frontiers in immunology · 2026Article
- Case Report: Successful treatment of steroid-refractory immune checkpoint inhibitor associated myocarditis with tofacitinib.Frontiers in immunology · 2026Article
- Guanylate-binding protein 5: a promising biomarker and therapeutic target.Infection and immunity · 2025Review
- Article
- Cancer-Related Immune Therapies: Bidirectional Implications From Cardiotoxicity to Emerging Cardiovascular Therapeutics: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Role of guanylate-binding protein 5 in inflammatory diseases, immune diseases, cancers, and its potential therapeutic implications.Inflammopharmacology · 2025Review
- Age-related alterations in gut homeostasis are microbiota dependent.NPJ biofilms and microbiomes · 2025Article
- Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy.Basic research in cardiology · 2025Review
- Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications.Current heart failure reports · 2024Review
- Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.Journal of translational medicine · 2024Observational
- Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors.World journal of clinical oncology · 2024Review
- Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.Current heart failure reports · 2024Review
- Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology.Genes & diseases · 2024Review
- Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.Circulation · 2024Article
- Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.Frontiers in cardiovascular medicine · 2024Article
- Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor.bioRxiv : the preprint server for biology · 2023Article
- Article
- Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human.Immunological reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment. Nevertheless, their increasing use leads to an increase of immune-related adverse events (irAEs). Among them, ICI-associated myocarditis (ICIM) is a rare irAE with a high mortality rate. We aimed to characterize the transcriptional changes of ICIM myocardial biopsies and their possible implications. Patients suspected for ICIM were assessed in the cardio-oncology units of University Hospitals Heidelberg and Kiel. Via RNA sequencing of myocardial biopsies, we compared transcriptional changes of ICIM (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.